Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of Creatine Formulations on Exercise and Cognitive Performance

10 de noviembre de 2026 actualizado por: Terence Moriarty, University of Northern Iowa

Effects of Creatine Monohydrate Versus a Multi-Ingredient Creatine Formulation on Exercise Performance, Cognitive Function, Hydration, and Gastrointestinal Tolerability

This study will examine whether a multi-ingredient creatine supplement produces different effects on exercise performance, cognitive function, hydration, and gastrointestinal symptoms compared with creatine monohydrate alone.

Approximately 16 healthy, physically active adults aged 18-40 years will participate. Each participant will take creatine monohydrate (5 grams per day) for 18 days and a multi-ingredient supplement containing creatine monohydrate (5 grams), sodium, potassium, magnesium, and taurine for another 18 days. The order of supplementation will be randomly assigned, with a 30-day break between conditions.

Participants will complete laboratory testing before and after each supplementation period. Testing will include bench press exercise to assess muscular endurance, repeated high-intensity cycling tests to assess exercise performance, and a computerized cognitive task to measure attention and reaction time. Researchers will also assess hydration, selected blood markers, perceived exertion, and gastrointestinal symptoms.

The findings may help determine whether adding electrolytes and taurine to creatine provides additional benefits or produces different physiological responses compared with creatine monohydrate alone.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

16

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Iowa
      • Cedar Falls, Iowa, Estados Unidos, 50614
        • Reclutamiento
        • Wellness and Recreation Center
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 40 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults aged 18-40 years.
  • Apparently healthy individuals who are physically active and capable of performing vigorous exercise.
  • Willing and able to complete repeated maximal-intensity cycling tests, bench press exercise, and cognitive assessments.
  • Willing to consume both assigned dietary supplement formulations for 18 days each, separated by a 30-day washout period.
  • Willing to refrain from taking additional creatine or electrolyte supplements during the study, including the washout period.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • History of cardiovascular, metabolic, renal, neurological, or musculoskeletal conditions that may contraindicate vigorous exercise or interfere with study outcomes.
  • Current injury or physical limitation that would prevent safe completion of the exercise testing procedures.
  • Current pregnancy or plans to become pregnant during the study.
  • Recent creatine supplementation prior to enrollment.
  • Current use of medications or dietary supplements that may interfere with creatine metabolism, hydration status, exercise performance, cognitive function, or participant safety.
  • Known allergy, intolerance, or contraindication to any ingredient in the study supplements.
  • Unwillingness or inability to comply with supplementation, washout, or laboratory testing requirements.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Creatine Monohydrate Followed by Multi-Ingredient Creatine

Participants will receive creatine monohydrate (5 g/day) with sugar-free flavoring for 18 consecutive days, followed by a 30-day washout period. Participants will then receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period.

Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Experimental: Multi-Ingredient Creatine Followed by Creatine Monohydrate

Participants will receive a multi-ingredient formulation containing creatine monohydrate (5 g/day), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) for 18 consecutive days, followed by a 30-day washout period. Participants will then receive creatine monohydrate (5 g/day) with sugar-free flavoring for an additional 18 days. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after each supplementation period.

Participants will consume 5 g/day of creatine monohydrate mixed with sugar-free flavoring for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

Participants will consume a multi-ingredient dietary supplement containing creatine monohydrate (5 g), sodium (500 mg), potassium (250 mg), magnesium (50 mg), and taurine (1 g) daily for 18 consecutive days. On the final day of supplementation, the supplement will be consumed approximately 60 minutes before laboratory testing. Exercise performance, cognitive function, hydration status, physiological responses, and gastrointestinal tolerability will be assessed before and after the supplementation period.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Total Bench Press Repetitions
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Total number of repetitions completed across three sets of bench press exercise at 70% of baseline one-repetition maximum (1RM), performed to volitional fatigue with one minute of rest between sets.

Baseline and Day 18 of each supplementation period.
Peak Power During Repeated Wingate Tests
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Peak power output (watts) measured during three consecutive 30-second Wingate cycling tests, performed with standardized recovery periods.

Baseline and Day 18 of each supplementation period.
Mean Power During Repeated Wingate Tests
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Mean power output (watts) measured during each of three 30-second maximal-effort Wingate cycling tests.

Baseline and Day 18 of each supplementation period.
Total Work During Repeated Wingate Tests
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Total mechanical work (kilojoules) completed across three 30-second Wingate cycling tests.

Baseline and Day 18 of each supplementation period.
Stroop Interference Reaction Time
Periodo de tiempo: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Cognitive performance assessed using a computerized Stroop task completed before exercise and during recovery between repeated Wingate tests. Reaction time (milliseconds) will be used to evaluate changes in cognitive performance as exercise-induced fatigue accumulates.

Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).
Stroop Task Accuracy
Periodo de tiempo: Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Percentage of correct responses during a computerized Stroop task administered before exercise and during recovery between repeated Wingate cycling tests.

Day 1 and Day 18 of each 18-day supplementation period (three assessments per day).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Wingate Fatigue Index
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Percentage decline in power output during repeated Wingate tests.

Baseline and Day 18 of each supplementation period.
Rating of Perceived Exertion
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Perceived exertion assessed using the Borg 6-20 scale following each Wingate.

Baseline and Day 18 of each supplementation period.
Blood Lactate Concentration
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Blood lactate concentration (mmol/L) measured following each Wingate.

Baseline and Day 18 of each supplementation period.
Urine Specific Gravity
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Urine specific gravity assessed before and after exercise to evaluate hydration status.

Baseline and Day 18 of each supplementation period.
Blood Sodium Concentration
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Sodium concentration measured using an i-STAT analyzer.

Baseline and Day 18 of each supplementation period.
Blood Potassium Concentration
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Potassium concentration measured using an i-STAT analyzer.

Baseline and Day 18 of each supplementation period.
Gastrointestinal Symptom Severity
Periodo de tiempo: Baseline and Day 18 of each supplementation period.

Daily 0-10 ratings of bloating, abdominal discomfort, nausea, diarrhea, constipation, reflux, and overall gastrointestinal discomfort.

Baseline and Day 18 of each supplementation period.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

13 de noviembre de 2026

Finalización primaria (Estimado)

31 de mayo de 2027

Finalización del estudio (Estimado)

31 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

5 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB-FY27-58

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir